Compass Therapeutics, Inc. (CMPX)
NCM – Real Time Price. Currency in USD
1.87
+0.04 (2.19%)
At close: May 12, 2026, 4:00 PM EDT
1.85
-0.02 (-1.05%)
Pre-market: May 13, 2026, 5:34 AM EDT
Find any stock by ticker or company name

NCM – Real Time Price. Currency in USD
1.87
+0.04 (2.19%)
At close: May 12, 2026, 4:00 PM EDT
1.85
-0.02 (-1.05%)
Pre-market: May 13, 2026, 5:34 AM EDT
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company’s lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
| Name | Position |
|---|---|
| Anna Gifford | Senior Manager of Communications & Chief of Staff |
| Dr. Cynthia A. Sirard M.D., Ph.D. | Chief Medical Officer |
| Dr. James Kranz Ph.D. | VP and Head of Chemistry Manufacturing & Controls |
| Dr. Thomas J. Schuetz M.D., Ph.D. | CEO & Vice Chairman |
| Mr. Arjun Prasad M.B.A., M.P.H. | Chief Commercial Officer |
| Mr. Barry Shin J.D., M.B.A. | Chief Financial Officer |
| Mr. Bing Gong Ph.D. | Chief Scientific Officer |
| Mr. Jonathan E. Anderman J.D. | Senior VP, General Counsel & Corporate Secretary |
| Ms. Karin Herrera B.A. | Senior VP & Head of Clinical Operations |
| Date | Type | Document |
|---|---|---|
| 2026-05-05 | 8-K | f8k_050426.htm |
| 2026-05-05 | 10-Q | cmpx20260331_10q.htm |
| 2026-04-29 | DEFA14A | edge20068103x2_defa14a.htm |
| 2026-04-29 | DEF 14A | edge20068103x1_def14a.htm |
| 2026-04-27 | 8-K | f8k_042526.htm |
| 2026-03-12 | S-8 | d110919ds8.htm |
| 2026-03-05 | 10-K | cmpx20251231_10k.htm |
| 2026-01-06 | 8-K | f8k_010626.htm |
| 2025-12-31 | DEL AM | d26360ddelam.htm |
| 2025-12-30 | S-3 | d26360ds3.htm |